HRP20230468T1 - Varijante ljudske alfa galaktozidaze - Google Patents
Varijante ljudske alfa galaktozidaze Download PDFInfo
- Publication number
- HRP20230468T1 HRP20230468T1 HRP20230468TT HRP20230468T HRP20230468T1 HR P20230468 T1 HRP20230468 T1 HR P20230468T1 HR P20230468T T HRP20230468T T HR P20230468TT HR P20230468 T HRP20230468 T HR P20230468T HR P20230468 T1 HRP20230468 T1 HR P20230468T1
- Authority
- HR
- Croatia
- Prior art keywords
- alpha galactosidase
- seq
- recombinant
- optionally
- galactosidase
- Prior art date
Links
- 108010030291 alpha-Galactosidase Proteins 0.000 title claims 14
- 102000005840 alpha-Galactosidase Human genes 0.000 title claims 14
- 108010049936 agalsidase alfa Proteins 0.000 claims 9
- 230000035772 mutation Effects 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 5
- 102000040430 polynucleotide Human genes 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 5
- 238000002360 preparation method Methods 0.000 claims 5
- 208000024720 Fabry Disease Diseases 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 230000037213 diet Effects 0.000 claims 2
- 235000005911 diet Nutrition 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (16)
1. Rekombinantna alfa galaktozidaza A i/ili biološki aktivan fragment rekombinantne alfa galaktozidaze A, naznačena time, da sadrži aminokiselinski slijed koji je najmanje oko 90%, najmanje oko 91%, najmanje oko 92%, najmanje oko 93%, najmanje oko 94%, najmanje oko 95%, najmanje oko 96%, najmanje oko 97%, najmanje oko 98%, ili najmanje oko 99% istovjetan slijedu SEQ ID NO: 5, pri čemu navedena alfa galaktozidaza A sadrži mutaciju na poziciji 206, gdje se pozicija numerira pozivanjem na SEQ ID NO: 5.
2. Rekombinantna alfa galaktozidaza A prema patentnom zahtjevu 1, naznačena time, da:
a) navedena mutacija na poziciji 206 je mutacija 206A, 206M, 206Q, 206R, 206T, 206E, 206G ili 206S;
b) navedena mutacija na poziciji 206 je mutacija 206A;
c) navedena alfa galaktozidaza A sadrži mutacije 206T/359S; i/ili
d) alfa galaktozidaza A se bira od bilo kojeg od sljedova SEQ ID NO: 10, 13, 18, 21, 24, 40, 42, 44, 46, 119-121, 236-435, 437-442, 444-687 i 689-733.
3. Rekombinantna alfa galaktozidaza A, naznačena time, da sadrži polipeptidni slijed SEQ ID NO: 15, 13, 10, 18, 40, 42, 44 ili 46.
4. Rekombinantna alfa galaktozidaza A prema bilo kojem od patentnih zahtjeva 1-3, naznačena time, da je navedena rekombinantna alfa galaktozidaza A:
a) temperaturno stabilnija nego alfa galaktozidaza A sa SEQ ID NO: 5;
b) stabilnija na pH 7,4 nego alfa galaktozidaza A sa SEQ ID NO: 5; opcionalno gdje je navedena rekombinantna alfa galaktozidaza A:
(i) stabilnija na pH 4,3 nego alfa galaktozidaza A sa SEQ ID NO: 5; ili
(ii) stabilnija kod izloženosti serumu nego alfa galaktozidaza A sa SEQ ID NO: 5;
c) deimunizirana alfa galaktozidaza A;
d) deimunizirana alfa galaktozidaza A odabrana od sljedova SEQ ID NO: 10, 13, 18, 21, 40, 42, 44, 46, 121, 236, 237, 239-337, 339-368, 370-373, 375, 376, 378-431, 433-435, 437-442, 444-453, 455-478, 480-498, 500-510, 512-550, 552-649, 651-687 i 689-733.
e) pročišćena; i/ili
f) izražava najmanje jedno poboljšano svojstvo odabrano od sljedećih: i) unaprijeđeno katalitičko djelovanje; ii) povećana tolerancija na pH 7,4; iii) povećana tolerancija na pH 4,3; iv) povećana tolerancija na serum; ili v) smanjeni imunogenicitet; ili kombinacija od bilo kojega od i), ii), iii), iv) ili v), u usporedbi s referentnim slijedom, opcionalno gdje navedeni referentni slijed je SEQ ID NO: 5 ili SEQ ID NO: 10.
5. Pripravak, naznačen time, da sadrži najmanje jednu rekombinantnu alfa galaktozidazu A prema bilo kojem od patentnih zahtjeva 1-4.
6. Rekombinantni polinukleotidni slijed, naznačen time, da kodira najmanje jednu rekombinantnu alfa galaktozidazu A koja je predstavljena u bilo kojem od patentnih zahtjeva 1-5, opcionalno gdje je navedeni polinukleotidni slijed kodonski optimiran.
7. Vektor ekspresije, naznačen time, da sadrži rekombinantni polinukleotidni slijed prema patentnom zahtjevu 6, opcionalno pritom je navedeni rekombinantni polinukleotidni slijed operabilno povezan s kontrolnim slijedom, primjerice gdje navedeni kontrolni slijed je promotor, opcionalno gdje navedeni promotor je heterologni promotor.
8. Stanica domaćina, naznačena time, da sadrži vektor ekspresije prema patentnom zahtjevu 7, opcionalno gdje je navedena stanica domaćina eukariotska stanica.
9. Postupak za proizvodnju varijante alfa galaktozidaze A, naznačen time, da obuhvaća kultiviranje navedene stanice domaćina prema patentnom zahtjevu 8, pod takvim uvjetima u kojima će navedena alfa galaktozidaza A kodirana putem navedenog rekombinantnog polinukleotidnog slijeda, biti proizvedena.
10. Postupak prema patentnom zahtjevu 9, naznačen time, da nadalje obuhvaća dobivanje navedene alfa galaktozidaze A, dok opcionalno postupak nadalje obuhvaća fazu pročišćavanja navedene alfa galaktozidaze A.
11. Farmaceutski pripravak, naznačen time, da sadrži enzimski pripravak prema patentnom zahtjevu 5.
12. Farmaceutski pripravak prema patentnom zahtjevu 11, naznačen time, da navedeni pripravak:
a) nadalje sadrži farmaceutski prihvatljiv nosač i/ili pomoćno sredstvo;
b) prikladan je za parenteralnu injekciju ili infuziju kod čovjeka; i/ili
c) služi za liječenje Fabryjeve bolesti.
13. Farmaceutski pripravak prema patentnom zahtjevu 11 ili 12, naznačen time, da je za uporabu u liječenju i/ili prevenciji simptoma Fabryjeve bolesti kod pojedinca.
14. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 13, naznačen time, da:
a) navedeni simptomi Fabryjeve bolesti se popravljaju;
b) navedeni pojedinac može jesti prema režimu prehrane koji manje ograničava sadržaj masti nego što je to slučaj kod režima prehrane potrebnih za pojedince kod kojih su izraženi simptomi Fabryjeve bolesti;
c) navedeni pojedinac je (i) malo dijete ili dijete, ili (ii) odrasla osoba ili mlada odrasla osoba.
15. Pripravak prema bilo kojem od patentnih zahtjeva 5, 11 i 12, naznačen time, da je za uporabu kao lijek.
16. Neterapijska uporaba pripravka prema patentnom zahtjevu 5, naznačena time, da je kao dodatak prehrani.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462095313P | 2014-12-22 | 2014-12-22 | |
| US201562216452P | 2015-09-10 | 2015-09-10 | |
| EP15874075.3A EP3237621B1 (en) | 2014-12-22 | 2015-12-02 | Human alpha-galactosidase variants |
| PCT/US2015/063329 WO2016105889A1 (en) | 2014-12-22 | 2015-12-02 | Human alpha-galactosidase variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230468T1 true HRP20230468T1 (hr) | 2023-11-10 |
Family
ID=56151383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230468TT HRP20230468T1 (hr) | 2014-12-22 | 2015-12-02 | Varijante ljudske alfa galaktozidaze |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US20170360900A1 (hr) |
| EP (2) | EP4234699A1 (hr) |
| JP (4) | JP6650943B2 (hr) |
| KR (2) | KR102438885B1 (hr) |
| AU (2) | AU2015370125B2 (hr) |
| BR (1) | BR112017013300A2 (hr) |
| CA (1) | CA2970638A1 (hr) |
| DK (1) | DK3237621T3 (hr) |
| ES (1) | ES2944889T3 (hr) |
| FI (1) | FI3237621T3 (hr) |
| HR (1) | HRP20230468T1 (hr) |
| HU (1) | HUE062016T2 (hr) |
| IL (1) | IL252479B (hr) |
| LT (1) | LT3237621T (hr) |
| PL (1) | PL3237621T3 (hr) |
| PT (1) | PT3237621T (hr) |
| RS (1) | RS64574B1 (hr) |
| SI (1) | SI3237621T1 (hr) |
| WO (1) | WO2016105889A1 (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3237621T (lt) | 2014-12-22 | 2023-09-25 | Codexis, Inc. | Žmogaus alfa-galaktozidazės variantai |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| EP3393501B1 (en) * | 2015-12-24 | 2023-06-07 | Oxyrane UK Limited | Human alpha-n-acetylgalactosaminidase polypeptide |
| US11708569B2 (en) | 2018-08-29 | 2023-07-25 | University Of Copenhagen | Modified recombinant lysosomal alpha-galactosidase A and aspartylglucoaminidase having low mannose-6-phosphate and high sialic acid |
| CA3123598A1 (en) * | 2018-12-20 | 2020-06-25 | Codexis, Inc. | Human alpha-galactosidase variants |
| JP2022545718A (ja) | 2019-08-30 | 2022-10-28 | コデクシス， インコーポレイテッド | 操作されたリパーゼ改変体 |
| US20220348896A1 (en) * | 2019-09-18 | 2022-11-03 | The Medical College Of Wisconsin, Inc. | Improved Alpha-Galactosidase Protein for Enzyme Replacement Therapy (ERT) and Methods of Use |
| EP4077679A4 (en) | 2019-12-20 | 2024-04-24 | Codexis Inc | MODIFIED ACID ALPHA-GLUCOSIDASE VARIANTS |
| WO2021173928A2 (en) * | 2020-02-28 | 2021-09-02 | Codexis, Inc. | Human alpha-galactosidase variants |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US753653A (en) | 1903-09-14 | 1904-03-01 | American Car & Foundry Co | Hopper-bottom car. |
| US5356804A (en) | 1990-10-24 | 1994-10-18 | Mount Sinai School Of Medicine Of The City Of New York | Cloning and expression of biologically active human α-galactosidase A |
| US6165793A (en) | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US20060257890A1 (en) | 1996-05-20 | 2006-11-16 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US6995017B1 (en) | 1994-02-17 | 2006-02-07 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US6309883B1 (en) | 1994-02-17 | 2001-10-30 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5928905A (en) | 1995-04-18 | 1999-07-27 | Glaxo Group Limited | End-complementary polymerase reaction |
| US6395547B1 (en) | 1994-02-17 | 2002-05-28 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6406855B1 (en) | 1994-02-17 | 2002-06-18 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| CN1151762A (zh) | 1994-06-30 | 1997-06-11 | 诺沃诺尔迪斯克生物技术有限公司 | 非毒性、非产毒性、非致病性镰孢属表达系统及所用启动子和终止子 |
| FI104465B (fi) | 1995-06-14 | 2000-02-15 | Valio Oy | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
| US6506602B1 (en) | 1996-03-25 | 2003-01-14 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6096548A (en) | 1996-03-25 | 2000-08-01 | Maxygen, Inc. | Method for directing evolution of a virus |
| US6458574B1 (en) * | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
| EP0935651B1 (en) * | 1996-09-13 | 2004-12-29 | Transkaryotic Therapies, Inc. | THERAPY FOR alpha-GALACTOSIDASE A DEFICIENCY |
| US7148054B2 (en) | 1997-01-17 | 2006-12-12 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| DE69835360T2 (de) | 1997-01-17 | 2007-08-16 | Maxygen, Inc., Redwood City | EVOLUTION Prokaryotischer GANZER ZELLEN DURCH REKURSIVE SEQUENZREKOMBINATION |
| US6326204B1 (en) | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| DK2270234T3 (da) | 1997-12-08 | 2013-06-03 | California Inst Of Techn | Fremgangsmåde til fremstilling af polynukleotid- og polypeptidsekvenser |
| US6365408B1 (en) | 1998-06-19 | 2002-04-02 | Maxygen, Inc. | Methods of evolving a polynucleotides by mutagenesis and recombination |
| JP4221100B2 (ja) | 1999-01-13 | 2009-02-12 | エルピーダメモリ株式会社 | 半導体装置 |
| US6376246B1 (en) | 1999-02-05 | 2002-04-23 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
| US6917882B2 (en) | 1999-01-19 | 2005-07-12 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
| US6436675B1 (en) | 1999-09-28 | 2002-08-20 | Maxygen, Inc. | Use of codon-varied oligonucleotide synthesis for synthetic shuffling |
| US6368861B1 (en) | 1999-01-19 | 2002-04-09 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
| US7024312B1 (en) | 1999-01-19 | 2006-04-04 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
| US7702464B1 (en) | 2001-08-21 | 2010-04-20 | Maxygen, Inc. | Method and apparatus for codon determining |
| US6961664B2 (en) | 1999-01-19 | 2005-11-01 | Maxygen | Methods of populating data structures for use in evolutionary simulations |
| EP1108783A3 (en) | 1999-01-19 | 2001-09-05 | Maxygen, Inc. | Oligonucleotide-mediated nucleic acid recombination |
| AU3391900A (en) | 1999-03-05 | 2000-09-21 | Maxygen, Inc. | Encryption of traits using split gene sequences |
| US7430477B2 (en) | 1999-10-12 | 2008-09-30 | Maxygen, Inc. | Methods of populating data structures for use in evolutionary simulations |
| US6519065B1 (en) | 1999-11-05 | 2003-02-11 | Jds Fitel Inc. | Chromatic dispersion compensation device |
| EP1272967A2 (en) | 2000-03-30 | 2003-01-08 | Maxygen, Inc. | In silico cross-over site selection |
| US20020095135A1 (en) * | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US7747391B2 (en) | 2002-03-01 | 2010-06-29 | Maxygen, Inc. | Methods, systems, and software for identifying functional biomolecules |
| US20050084907A1 (en) | 2002-03-01 | 2005-04-21 | Maxygen, Inc. | Methods, systems, and software for identifying functional biomolecules |
| ES2564570T3 (es) | 2002-03-01 | 2016-03-23 | Codexis Mayflower Holdings, Llc | Métodos, sistemas y software para la identificación de biomoléculas funcionales |
| JP4851687B2 (ja) | 2002-03-09 | 2012-01-11 | マキシジェン， インコーポレイテッド | 定向進化のための交叉点の最適化 |
| ES2367257T3 (es) * | 2002-04-25 | 2011-10-31 | Shire Human Genetic Therapies, Inc. | Tratamiento de deficit de alfa-galactosidasa a. |
| EP1869174B1 (en) | 2005-03-10 | 2015-02-18 | BASF Enzymes LLC | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
| US7531341B1 (en) | 2006-06-12 | 2009-05-12 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7534595B2 (en) | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7537923B2 (en) | 2007-08-17 | 2009-05-26 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| WO2009102901A1 (en) | 2008-02-12 | 2009-08-20 | Codexis, Inc. | Method of generating an optimized, diverse population of variants |
| US8504498B2 (en) | 2008-02-12 | 2013-08-06 | Codexis, Inc. | Method of generating an optimized, diverse population of variants |
| EP2285958B1 (en) | 2008-06-13 | 2016-03-09 | Codexis, Inc. | Method of synthesizing polynucleotide variants |
| US8383346B2 (en) | 2008-06-13 | 2013-02-26 | Codexis, Inc. | Combined automated parallel synthesis of polynucleotide variants |
| US20090312196A1 (en) | 2008-06-13 | 2009-12-17 | Codexis, Inc. | Method of synthesizing polynucleotide variants |
| US9194011B2 (en) * | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
| US8876066B1 (en) | 2009-12-17 | 2014-11-04 | Progressive Fastening, Inc. | Hanger with bolt closures |
| ES2582459T3 (es) | 2010-02-04 | 2016-09-13 | Biomarin Pharmaceutical Inc. | Composiciones de variantes de fenilalanina amoníaco-liasa de procariotas y métodos de uso de sus composiciones |
| NZ623294A (en) * | 2010-03-02 | 2015-10-30 | Protalix Ltd | Stabilized alpha-galactosidase and uses thereof |
| BR112013031553A2 (pt) | 2011-06-08 | 2020-11-10 | Shire Human Genetic Therapies, Inc. | composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena |
| DK2726651T3 (en) | 2011-06-28 | 2019-01-28 | Codexis Inc | PROTEIN INVARIANT GENERATION BY REGION SHUFFLING |
| EP2825647A4 (en) | 2012-03-15 | 2015-10-14 | Codexis Inc | METHODS OF GENE REARRANGING |
| DK2839001T3 (en) * | 2012-04-18 | 2017-12-11 | Vib Vzw | METHODS AND PROCEDURES FOR THE PREPARATION OF IMPROVED PROTEINS |
| WO2014120819A1 (en) | 2013-01-31 | 2014-08-07 | Codexis, Inc. | Methods, systems, and software for identifying bio-molecules with interacting components |
| CN109872771A (zh) | 2013-09-27 | 2019-06-11 | 科德克希思公司 | 基于定向进化的方法、装置和系统 |
| RU2016116253A (ru) | 2013-09-27 | 2017-11-01 | Кодексис, Инк. | Автоматизированный скрининг вариантов фермента |
| LT3237621T (lt) * | 2014-12-22 | 2023-09-25 | Codexis, Inc. | Žmogaus alfa-galaktozidazės variantai |
| CA3123598A1 (en) | 2018-12-20 | 2020-06-25 | Codexis, Inc. | Human alpha-galactosidase variants |
-
2015
- 2015-12-02 LT LTEPPCT/US2015/063329T patent/LT3237621T/lt unknown
- 2015-12-02 FI FIEP15874075.3T patent/FI3237621T3/fi active
- 2015-12-02 HR HRP20230468TT patent/HRP20230468T1/hr unknown
- 2015-12-02 PT PT158740753T patent/PT3237621T/pt unknown
- 2015-12-02 JP JP2017533453A patent/JP6650943B2/ja active Active
- 2015-12-02 RS RS20230405A patent/RS64574B1/sr unknown
- 2015-12-02 ES ES15874075T patent/ES2944889T3/es active Active
- 2015-12-02 PL PL15874075.3T patent/PL3237621T3/pl unknown
- 2015-12-02 AU AU2015370125A patent/AU2015370125B2/en active Active
- 2015-12-02 WO PCT/US2015/063329 patent/WO2016105889A1/en active Application Filing
- 2015-12-02 DK DK15874075.3T patent/DK3237621T3/da active
- 2015-12-02 KR KR1020177019488A patent/KR102438885B1/ko active IP Right Grant
- 2015-12-02 HU HUE15874075A patent/HUE062016T2/hu unknown
- 2015-12-02 EP EP23168236.0A patent/EP4234699A1/en active Pending
- 2015-12-02 EP EP15874075.3A patent/EP3237621B1/en active Active
- 2015-12-02 KR KR1020227029553A patent/KR20220123342A/ko not_active Application Discontinuation
- 2015-12-02 SI SI201531947T patent/SI3237621T1/sl unknown
- 2015-12-02 CA CA2970638A patent/CA2970638A1/en active Pending
- 2015-12-02 BR BR112017013300A patent/BR112017013300A2/pt not_active Application Discontinuation
- 2015-12-02 US US15/529,383 patent/US20170360900A1/en not_active Abandoned
-
2017
- 2017-05-24 IL IL252479A patent/IL252479B/en active IP Right Grant
-
2019
- 2019-01-23 JP JP2019009294A patent/JP2019076110A/ja not_active Withdrawn
-
2020
- 2020-08-05 US US16/985,742 patent/US10973888B2/en active Active
- 2020-08-05 US US16/985,761 patent/US11278600B2/en active Active
- 2020-08-05 US US16/985,788 patent/US11497798B2/en active Active
- 2020-10-05 JP JP2020168384A patent/JP2021003129A/ja active Pending
-
2021
- 2021-03-09 US US17/196,858 patent/US20210244804A1/en active Pending
-
2022
- 2022-05-03 AU AU2022202939A patent/AU2022202939A1/en active Pending
- 2022-05-11 JP JP2022078184A patent/JP2022097653A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230468T1 (hr) | Varijante ljudske alfa galaktozidaze | |
| Redwan et al. | Potential lactoferrin activity against pathogenic viruses | |
| Tan et al. | Venomics, lethality and neutralization of Naja kaouthia (monocled cobra) venoms from three different geographical regions of Southeast Asia | |
| BR112018071199A2 (pt) | célula t, população isolada de células t, composição farmacêutica, método de tratamento, método para gerar uma célula t, vetor, célula tronco | |
| US9637532B2 (en) | Virus like particle comprising PD-1 antigen or PD-1 ligand antigen | |
| HRP20190928T1 (hr) | Modificirani fenilalanin amonijak-liazni polipeptidi | |
| KR20180011130A (ko) | 면역 신호전달 초래 및/또는 창자 장벽 기능에 영향 및/또는 대사 상태를 조절하기 위한 폴리펩티드의 용도 | |
| Shen et al. | Expression of recombinant AccMRJP1 protein from royal jelly of Chinese honeybee in Pichia pastoris and its proliferation activity in an insect cell line | |
| WO2021093134A1 (zh) | 一组蛇神经生长因子及蛇神经生长因子前体在治疗老年痴呆上的应用 | |
| JP2018519362A (ja) | 炎症性疾患の予防または治療用ペプチド及びこの用途 | |
| PH12015502005B1 (en) | New stable pentadecapeptide salts, a process for preparation thereof, a use thereof in the manufacture of pharmaceutical preparations and a use thereof in therapy | |
| JP5581485B2 (ja) | Ｅｃ−ｓｏｄの新規な用途及びその製造方法 | |
| Zhao et al. | Construction of the recombinant vaccine based on T-cell epitope encoding Der p1 and evaluation on its specific immunotherapy efficacy | |
| JP2008195618A (ja) | 経口免疫寛容を誘導するペプチド組成物及びその製造方法 | |
| US20230265131A1 (en) | Amuc-1100 polypeptide variants for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status | |
| Huo et al. | Molecular cloning of chicken IL-7 and characterization of its antiviral activity against IBDV in vivo | |
| Medrano et al. | Efficient plant-based production of chicken interleukin-12 yields a strong immunostimulatory cytokine | |
| JP6573294B2 (ja) | 炎症性疾患の予防または治療用ペプチド及びその用途 | |
| Ohya et al. | Ability of orally administered IFN-α-containing transgenic potato extracts to inhibit Listeria monocytogenes infection | |
| EP3904375A1 (en) | Type 1 interferon neutralizing fc-fusion protein and use thereof | |
| JP5598504B2 (ja) | 経口免疫寛容を誘導するペプチド組成物及びその製造方法 | |
| Fiebiger et al. | A live microbial biotherapeutic product for induction of allergy-protective immunity | |
| Xu et al. | Enhancement of recombinant human interleukin-22 production by fusing with human serum albumin and supplementing N-acetylcysteine in Pichia Pastoris | |
| Xie et al. | A novel bifunctional protein TNFR2-Fc-IL-1ra (TFI): expression, purification and its neutralization activity of inflammatory factors | |
| CA2995985A1 (en) | Enzymatic fractions with anti-inflammatory activity |